Combination therapy with BRAF plus MEK inhibitors (BRAFi+MEKi) has transformed the treatment landscape and improved the clinical outcomes of patients with melanoma harboring BRAFv600 mutations [1,2,3,4,5,6,7]. This evidence concerns the gene MAP2K7 and melanoma.